OCULAR THERAPEUTIX, INC (OCUL) Debt Components
- 2023-09-30: Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Notes PayableUSD (m); Long-term DebtUSD (m).
- 2023-06-30: Notes Payable, CurrentUSD $2.08M; Long-term Line of CreditUSD (m); Notes PayableUSD (m); Long-term DebtUSD (m).
- 2022-12-31: Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Notes PayableUSD (m); Long-term DebtUSD (m).
- 2021-09-30: Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Notes PayableUSD $24.94M; Long-term DebtUSD (m).
OCULAR THERAPEUTIX, INC Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD | Long-term Line of Credit USD | Notes Payable USD | Long-term Debt USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Periodic Payment, Interest USD | Line of Credit Facility, Periodic Payment, Principal USD | Line of Credit Facility, Annual Principal Payment USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Unamortized Premium USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $37.50M | (m) | (m) |
| 2023-06-30 | $2.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $37.50M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $24.94M | (m) | $25.00M | (m) | (m) | (m) | $25.00M | (m) | $118.00K | (m) |
| 2021-06-30 | (m) | (m) | $24.89M | (m) | $25.00M | (m) | (m) | (m) | $25.00M | (m) | $124.00K | (m) |
| 2021-03-31 | $8.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $8.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $25.23M | (m) | (m) | (m) | (m) | (m) | $25.00M | (m) | $129.00K | (m) |
| 2020-09-30 | $6.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $4.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $2.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $25.00M | $24.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $217.00K | (m) |
| 2018-09-30 | $6.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $6.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $6.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $5.54M | $18.00M | $18.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $205.00K | (m) |
| 2017-09-30 | $3.99M | (m) | (m) | $18.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $2.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $897.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $1.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $3.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $2.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $1.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $5.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $4.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $2.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $1.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $133.00K |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | 6 month · $3.44M | 6 month · $15.00M | 6 month · $18.44M | (m) | (m) | (m) | (m) |
| 2014-06-30 | $1.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $1.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |